(June 1, 2017) A study, published last month in Gynecologic Oncology, focused on an area of ovarian cancer that is rarely talked about: the quality of life (QOL) for long … Continued
The White House has released a proposed budget for FY2018 that makes drastic cuts to the budgets for the National Institute of Health (NIH) and Centers for Disease Control and … Continued
(May 25, 2017) A retrospective study, published earlier this month in Obstetrics & Gynecology, looked at when women with ovarian cancer developed blood clots. One in four women diagnosed with … Continued
(May 22, 2017) A recent study from the Netherlands found that a combination of cognitive behavior therapies had a positive effect on FCR, or Fear of Cancer Recurrence. Eighty-eight cancer survivors, … Continued
(May 2, 2017) A study, published in Gynecologic Oncology, revealed the importance of tumor antigen NY-ESO-1 for ovarian cancer patients. This tumor antigen, although not normally found in healthy cells, … Continued
(April 26, 2017) A study recently published in Cancer evaluates the effect that cediranib, a drugs that stops the growth of new blood vessels, has on a patient’s quality of … Continued
(April 25, 2017) Researchers from Roswell Park Cancer Institute used data from 15 different studies that were part of the Ovarian Cancer Association Consortium, partially funded by OCRFA, to examine … Continued
A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2 … Continued
(April 21, 2017) Endometriosis, a condition where the tissue that lines the inside of the uterus grows outside the uterus, has been found to be associated with an increased risk … Continued
(April 20, 2017) Researchers from the National Cancer Institute assessed trends in the receipt of guideline care and 2-year cause-specific survival for women diagnosed with ovarian cancer. The study included … Continued
(April 7, 2017) A major new study published in Science claims that the reason why many people get cancer is simply just bad luck. It’s normal for people to seek … Continued
(March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
